Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H3S3
UPID:
TMPS5_HUMAN
Alternative names:
Spinesin
Alternative UPACC:
Q9H3S3
Background:
Transmembrane protease serine 5, also known as Spinesin, is a protein that may play a crucial role in hearing. This protein is characterized by its transmembrane nature and serine protease activity, suggesting a specific function in cellular processes.
Therapeutic significance:
Understanding the role of Transmembrane protease serine 5 could open doors to potential therapeutic strategies. Its involvement in auditory functions hints at the possibility of developing treatments for hearing impairments.